277 results about "Mucositis" patented technology

A method for simultaneously treating mucositis and fungal infection in a mammal in need thereof, said method comprising administering to said mammal an effective amount of an anti-mucositis and anti-fungal pharmaceutical composition consisting of a tetracycline compound in an amount that is effective to simultaneously treat mucositis and fungal infection, but has substantially no antibiotic activity.

Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.

Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and / or erosive disorders of mucous membranes, especially mucositis.

The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines or amino thiols formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

The present invention is directed to methods of treating or protecting mucosal tissue from damage associated with radiation and / or chemotherapeutic treatment of cancers, by the topical application of amifostine and related compounds. These methods avoid the side effects of systemically applied radio / chemo protectants. The invention is also directed to treatment and prevention of infections associated with mucositis by topical application of amifostine and related compounds.

An ultrasonic toothbrush having spatially extended functionality to treat various oral diseases in addition to removing plaque and treating gingivitis is disclosed. In addition to the ultrasonically activated bristles, the toothbrush incorporates a multi directional ultrasound transducer system, which spatially irradiates the oral cavity with ultrasonic pressure waves, operational to loosen plaque, to remove periodontal bacteria from teeth and gums, and to simultaneously treat and destroy disease causing bacteria and bacterial chains on the inside surfaces of cheeks and lips, providing relief from Recurring Aphthous Stomatitis, Lichen Planus, and Mucositis. Various configurations are disclosed, including user removable and replaceable brush heads and ultrasound treatment heads. A motorized version featuring sonic frequency orbital vibration brush head and bristle tufts is described.

A method for treating oral mucositis in a subject comprises topically administering to an oral mucosal surface of the subject phenyloin or a pharmaceutically acceptable salt thereof in an amount effective to inhibit mucosal degeneration or promote mucosal regeneration, and optionally an analgesic agent in an amount effective, in combination with the phenyloin or salt thereof, to reduce pain associated with the oral mucositis. The phenyloin or salt thereof and optionally the analgesic agent can be administered in a pharmaceutical composition comprising an excipient vehicle suitable for intraoral administration, said composition being bioadhesive to an oral mucosal surface, for example having at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to said surface.

The invention features a method for the treatment or prevention of mucositis in an individual undergoing or preparing to undergo cancer treatment. The method includes administering a therapeutically effective amount of an inhibitor of NF-.kappa.B to an individual undergoing or preparing to undergo a treatment for cancer. In certain embodiments, the inhibitor is a compound having the formula: 1 where R.sub.1 and R.sub.4 are OH, and R.sub.2 and R.sub.3 are independently OH or H, provided that when R.sub.1 and R.sub.2 are both OH, R.sub.1 and R.sub.2 cannot be disposed ortho to one another, and when R.sub.3 and R.sub.4 are both OH, R.sub.3 and R.sub.4 cannot be disposed ortho to one another. The compounds of formula I may be cis or trans.

The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.

The present invention for the first time discloses a method and a kit of parts for treating a periodontal disease, such as periimplantitis, gingivitis, periodontitis and / or periimplant mucositis, caused by microorganisms that colonize a tooth and / or implant surface at, above and / or below the gingival margin, and which reside in a biofilm either subgingival and / or supragingival, characterized by employing a surgical process leading to substantively removing, destroying, killing and / or disrupting and / or inhibiting growth and / or regrowth of a pathogenic biofilm at a site of a microbial infection in a patient suffering from a periodontal disease. Said method comprises, and said kit of parts comprises the means for; cleaning disinfecting and / or debriding the site of microbial infection mechanically and sequentially using first at least one cleaning and / or disinfecting agent with an immediate bactericidal effect, such as a NaClO solution, and thereafter at least one cleaning and / or disinfecting agent with a sustainable bactericidal effect, such as a CHX solution.

A therapeutic composition of deglycyrrizinated glycyrrhiza extract, Centella extract, Angelica Root extract, green tea extract, stilbene, and Aloe extract.

A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers.

The present invention concerns the use of platelet lysate for treating and / or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and / or prevention of mucositis and of corneal lesions is described.

In certain aspects, the present invention provides compositions and methods for treating mucositis.

The invention features devices and methods for delivering drugs to the oral cavity in order to treat mucositis, stomatitis, and other disorders of the oral cavity.

The present invention is directed to methods and compositions of treating or preventing epithelial lining tissue damage from dermatitis or mucositis induced by radiation exposure and / or chemotherapy, by applying to skin, mucosa or other tissues of the body an amount of a therapeutic composition which comprises a histone deacetylase inhibitor formulated with at least one pharmaceutically acceptable biocompatible polymer or carrier, or pharmaceutically acceptable salts in an amount sufficient to delay onset or decrease severity of the signs and symptoms of dermatitis and mucositis in cancer therapy. Such therapeutic compositions have the advantage of prolonged retention and sustained action of the histone deacetylase inhibitor in the skin, mucosa or other tissues of the body. The invention is also directed to treatment and prevention of gastrointestinal distress and cancer-related fatigue syndrome that are associated with mucositis in cancer therapy.

The present invention provides a method for preventing or delaying the onset of oral mucositis, including the onset of ulcerative or severe OM, in a patient receiving cancer therapy. The method comprises administering to the patient an effective regimen of γ-D-glutamyl-L-tryptophan (SCV-07) over the course of therapy. The regimen, which includes scheduled doses of SCV-07 with respect to radiation exposure and / or chemotherapy, is effective for preventing or delaying the onset of OM. In accordance with the invention, the patient is more able to complete the planned course of cancer therapy (including chemotherapy and / or radiation therapy), by maintaining a sufficient nutritional state, and by avoiding the significant pain and discomfort associated with OM.

The present invention relates to administration of milk fat or a milk fat analogue, optionally with at least one additional therapeutic factor, preferably lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof, to inhibit tumour formation or growth, maintain or improve one or more of the white blood cell count, the red blood cell count, or the myeloid cell count, reduce cachexia, mucositis, and anemia, stimulate the immune system and treat or prevent cancer and the symptoms of cancer and side-effects of cancer therapies. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin / low molecular weight heparin derivative.

The present invention is directed to a method for alleviating mucositis, sassociated with radiation and chemotherapy, via the administration of an oral rehydration solution.

The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines or amino thiols formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

The invention discloses a preparation method for oral nursing solution for preventing the oral mucositis caused by chemotherapy, for solving a problem of prevention for the oral mucositis caused by chemotherapy. The raw materials of the oral nursing solution comprise serissa serissoides, fructus ligustri lucidi, ficus virens leaves, sarcandra glabra, radix rehmanniae, radix scrophulariae, radix ophiopogonis, radix adenophorae and rhizoma anemarrhenae; and the preparation method is characterized by comprising the following steps of: (1) distilling the serissa serissoides, the fructus ligustri lucidi, the ficus virens leaves and the sarcandra glabra with steam to obtain a distillate; (2) adding the radix rehmanniae, the radix scrophulariae, the radix ophiopogonis, the radix adenophorae and the rhizoma anemarrhenae in the dregs of the distilled raw material medicines, and decocting with water to obtain a filtrate; (3) centrifuging the filtrate to obtain the supernatant, adding the distillate, adding water for injection, and then performing ultrafiltration; and (4) filling, sterilizing and packaging the ultrafiltrate. Clinical experiments prove that the oral nursing solution prepared by the method disclosed by the invention has characteristics of good curative effect and high safety for preventing the oral mucositis caused by chemotherapy, and is worthy of clinical application andpopularization.

Polyamine effectors are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more polyamine effectors formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin / low molecular weight heparin derivative.

The invention relates generally to the field of mucositis. More particularly, the present invention relates to methods and compositions for treating and preventing mucositis. In particular for treating or preventing oral mucositis, especially stomatitis and esophagitis. The invention generally relates to the use of recombinant non-pathogenic and non-invasive microorganisms, in particular recombinant bacterium or yeast expressing a trefoil peptide in particular in combination with one or more factors that target the mucus, tight junctions or extracellular matrix and / or factors typically used in the treatment of mucositis.